Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: infi.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/18/2021 | $9.00 | Buy | HC Wainwright & Co. |
| 8/2/2021 | $6.00 | Neutral → Overweight | JP Morgan |
| 7/28/2021 | $4.00 → $14.00 | Equal-Weight → Overweight | Wells Fargo |
| 7/7/2021 | $7.00 | Buy | B. Riley Securities |
HC Wainwright & Co. initiated coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $9.00
JP Morgan upgraded Infinity Pharmaceuticals from Neutral to Overweight and set a new price target of $6.00
Wells Fargo upgraded Infinity Pharmaceuticals from Equal-Weight to Overweight and set a new price target of $14.00 from $4.00 previously
B. Riley Securities resumed coverage of Infinity Pharmaceutical with a rating of Buy and set a new price target of $7.00
Truist initiated coverage of Infinity Pharmaceutical with a rating of Buy and set a new price target of $12.00
Wells Fargo reiterated coverage of Infinity Pharmaceuticals with a rating of Equal-Weight and set a new price target of $4.00 from $2.00 previously
Piper Sandler initiated coverage of Infinity Pharmaceuticals with a rating of Overweight and set a new price target of $7.00
Piper Sandler initiated coverage of Infinity Pharmaceuticals with a rating of Overweight and set a new price target of $7.00
B. Riley resumed coverage of Infinity Pharmaceuticals with a rating of Buy and set a new price target of $8.00 from $4.50 previously
Oppenheimer reiterated coverage of Infinity Pharmaceuticals with a rating of Outperform and set a new price target of $9.00 from $5.50 previously